Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Combination Eye Drops Improve Compliance: Prof. Yamamoto
April 5, 2010
- Application for Eritoran to Be Delayed Until March 2011: Eisai
April 5, 2010
- IFN Beta + Ribavirin Added to First-Line Therapy for Hepatitis C
April 5, 2010
- Alogliptin Applied for Combination with SU, BU as Additional Indications
April 5, 2010
- Cooperation of Pharmacists and Nurses Is Necessary for XELOX Therapy
April 5, 2010
- Dr Kondo Reappointed PMDA Chief Executive
April 5, 2010
- Erbitux Approved for Use in First-Line Therapy
April 5, 2010
- NovoSeven Approved for Bleeding in Congenial FVII Deficiency Patients
April 5, 2010
- Shionogi to Break from Long-Listed Drugs
April 5, 2010
- Korosho to Lift 14-Day Limit on Prescriptions of Thalidomide
April 5, 2010
- Hisamitsu Launches Fentanyl Transdermal System in the US
April 5, 2010
- Korosho Explains New Premium to Semi-Public Hospital Groups
April 5, 2010
- Research Funds Should Be Provided Based on Contracts: Dr Imamura
April 5, 2010
- Kitasato Univ. to Kick Off Global Clinical Research Center
April 5, 2010
- Place Top-Priority on Elimination of Bulk-Buying by Sum Value
April 5, 2010
- Keio Univ. to Promote Global Clinical Research
April 5, 2010
- All MRs from Eisai to Promote Oncology Products
April 5, 2010
- Korosho to Review Its Policy Re Clinical Trial Core Hospitals
April 5, 2010
- Sucampo Applies for Arbitration Regarding Amitiza Agreement with Takeda
April 5, 2010
- Ono Ties Up with BioSeek for Bioactive Lipid Drug Discovery
April 5, 2010
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…